Related Experiment Video

Updated: Apr 4, 2026

LINE-1 Methylation Analysis in Mesenchymal Stem Cells Treated with Osteosarcoma-Derived Extracellular Vesicles
12:18

LINE-1 Methylation Analysis in Mesenchymal Stem Cells Treated with Osteosarcoma-Derived Extracellular Vesicles

Published on: February 1, 2020

6.3K

Identification of genes associated with methotrexate resistance in methotrexate-resistant osteosarcoma cell lines

Xiao-Rong Yang1, Yan Xiong2, Hong Duan3

  • 1Department of Operation Room, West China Hospital, Sichuan University, No 37, Guo Xue Lane, Chengdu, Sichuan, 610041, People's Republic of China. jafsdfdfs@163.com.

Journal of Orthopaedic Surgery and Research
|September 5, 2015
PubMed
Abstract

Insights

Methotrexate resistance in osteosarcoma is linked to altered gene expression. Key genes in aminoacyl-tRNA biosynthesis and cell cycle pathways may drive this resistance, offering potential therapeutic targets.

Area of Science:

  • Molecular Biology
  • Genomics
  • Cancer Research

Background:

  • Osteosarcoma is a primary bone cancer with significant treatment challenges.
  • Methotrexate (MTX) is a chemotherapy agent used in osteosarcoma treatment.
  • Understanding MTX resistance mechanisms is crucial for improving patient outcomes.

Purpose of the Study:

  • To investigate the molecular mechanisms of methotrexate (MTX) resistance in osteosarcoma.
  • To identify differentially expressed genes (DEGs) associated with MTX resistance.
  • To explore the functional roles of these DEGs in osteosarcoma progression.

Main Methods:

  • Microarray data (GSE16089) from MTX-sensitive and resistant osteosarcoma cells were analyzed.
  • Differentially expressed genes (DEGs) were identified and functionally annotated using GO and KEGG databases.
  • Transcription factors (TFs), tumor-associated genes (TAGs), and protein-protein interaction (PPI) networks were constructed.

Main Results:

  • 690 up-regulated and 626 down-regulated genes were identified.
  • Up-regulated genes were linked to transfer RNA (tRNA) aminoacylation (e.g., AARS, PARS2).
  • Down-regulated genes were associated with the mitotic cell cycle (e.g., AURKA, CCNB1, CDK1, CENPA).

Conclusions:

  • Genes such as AARS, AURKA, AURKB, CENPA, CCNB1, CCNE2, and CDK1 may contribute to MTX resistance.
  • These genes are implicated in aminoacyl-tRNA biosynthesis, cell cycle regulation, and p53 signaling pathways.
  • Identifying these genes provides insights into potential therapeutic strategies for overcoming MTX resistance in osteosarcoma.

More Related Videos

MeRIP-qPCR Assay for Detecting m6A Modification Levels of Specific RNA in Osteosarcoma Cells05:16

MeRIP-qPCR Assay for Detecting m6A Modification Levels of Specific RNA in Osteosarcoma Cells

Published on: December 30, 2025

391
Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models09:58

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models

Published on: December 9, 2016

14.5K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
68